Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer

Fig. 2

Kaplan-Meier curve of cancer-specific survival in 77 UC patients treated with chemotherapy against recurrence and/or metastasis according to CD44v9 expression. Patients were allocated into the CD44v9-positive group (N = 64) or CD44v9-negative group (N = 13) based on a cut-off level of 5% in CD44v9 density. Cancer-specific survival rates were significantly lower in the CD44v9-positive group than in the CD44v9-negative group (p = 0.008 by log-rank test)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us